Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745355 | 0.92 | PDE4B (0.52) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5744498 | 0.91 | PDE4B (0.47) | PDE4BPDE4APDE4DKMT2ACYP3A4 | |
| SCHEMBL5747038 | 0.90 | PDE4B (0.47) | UBE2MDCUN1D1PDE4BPDE4APDE4D | |
| SCHEMBL5747017 | 0.88 | PDE4B (0.50) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5745954 | 0.88 | PDE4B (0.56) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5744719 | 0.88 | PDE4B (0.48) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5747650 | 0.88 | PDE4B (0.47) | UBE2MDCUN1D1PDE4BPDE4APDE4D | |
| SCHEMBL5744925 | 0.88 | PDE4B (0.49) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5746109 | 0.87 | PDE4B (0.48) | PDE4BPDE4APDE4DCYP3A4CYP2C9 | |
| SCHEMBL5745995 | 0.87 | PDE4B (0.51) | PDE4BPDE4APDE4DCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651635-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | LMNA 312/4885UBE2M 3886/4885DCUN1D1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.